Hérvè Chambost

6.7k total citations · 2 hit papers
134 papers, 3.8k citations indexed

About

Hérvè Chambost is a scholar working on Hematology, Immunology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Hérvè Chambost has authored 134 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Hematology, 19 papers in Immunology and 17 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Hérvè Chambost's work include Hemophilia Treatment and Research (65 papers), Platelet Disorders and Treatments (40 papers) and Blood Coagulation and Thrombosis Mechanisms (37 papers). Hérvè Chambost is often cited by papers focused on Hemophilia Treatment and Research (65 papers), Platelet Disorders and Treatments (40 papers) and Blood Coagulation and Thrombosis Mechanisms (37 papers). Hérvè Chambost collaborates with scholars based in France, United Kingdom and United States. Hérvè Chambost's co-authors include Nicolas van Baren, Pierre G. Coulie, Thierry Boon, Frédéric Lehmann, Alessandro Moretta, Jean‐François Baurain, Hideyuki Ikeda, Charles De Smet, Bernard Lethé and Massimo Vitale and has published in prestigious journals such as Journal of Biological Chemistry, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Hérvè Chambost

123 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor

1997 639 citations Hérvè Chambost et al. profile →
Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males

2019 265 citations Hérvè Chambost et al. profile →

Peers

Countries citing papers authored by Hérvè Chambost

Since Specialization

Citations

This map shows the geographic impact of Hérvè Chambost's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hérvè Chambost with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hérvè Chambost more than expected).

Fields of papers citing papers by Hérvè Chambost

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hérvè Chambost. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hérvè Chambost. The network helps show where Hérvè Chambost may publish in the future.

Co-authorship network of co-authors of Hérvè Chambost

This figure shows the co-authorship network connecting the top 25 collaborators of Hérvè Chambost. A scholar is included among the top collaborators of Hérvè Chambost based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hérvè Chambost. Hérvè Chambost is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	F8 gene variants influence the response to desmopressin in hemophilia A carriers 2025 ·Blood ·Benoît Guillet, Roseline d’Oiron, Marc Trossaërt, B. Wibaut, Brigitte Pan‐Petesch, (unknown), (unknown), (unknown), (unknown), Céline Falaise, Christine Biron‐Andréani, (unknown), Brigitte Tardy, (unknown), Hérvè Chambost, (unknown), (unknown), Xavier Delavenne	0
2	Impact of Systematic Joint Examination (Ultrasound, Functional and Physical) on Treatment Management Decisions in Patients With Haemophilia A in France: Final Data From the Prospective, Observational A‐MOVE Study 2025 ·Haemophilia ·(unknown), Virginie Barbay, (unknown), (unknown), Aurélien Lebreton, Brigitte Pan‐Petesch, (unknown), (unknown), Laurent Frenzel, Sandrine Jousse‐Joulin, Hérvè Chambost, (unknown), (unknown), (unknown), Mustapha Zidi, (unknown), Yohann Repessé, (unknown)	0
3	Relationship between plasma tissue Factor Pathway Inhibitor (TFPI) levels, thrombin generation and clinical risk of bleeding in patients with severe haemophilia A or B 2024 ·Haemophilia ·Brigitte Tardy, (unknown), Hérvè Chambost, Anne Lienhart, (unknown), Pierre‐Emmanuel Morange, Céline Falaise, Fanny Collange, Yesim Dargaud, (unknown), (unknown), B. Wibaut, Emmanuelle Jeanpierre, Philippe Nguyên, (unknown), Bernard Tardy	1
4	Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis 2023 ·Research and Practice in Thrombosis and Haemostasis ·Amy D. Shapiro, Hérvè Chambost, Margareth C. Ozelo, (unknown), (unknown), (unknown), Elena Santagostino	1
5	Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres 2023 ·Haemophilia ·Susanna Ranta, Jayashree Motwani, Jan Blatný, (unknown), Manuel Carção, Hérvè Chambost, Carmen Escuriola, Kathelijn Fischer, Mutlu Kartal‐Kaess, (unknown), Gili Kenet, Christoph Male, Beatrice Nolan, Roseline d’Oiron, Martin Olivieri, Ester Zápotocká, Nadine G. Andersson, Christoph Königs	8
6	Whole F9 gene sequencing identified deep intronic variations in genetically unresolved hemophilia B patients 2023 ·Journal of Thrombosis and Haemostasis ·(unknown), (unknown), Nicolas Chatron, Brigitte Tardy, (unknown), Hérvè Chambost, Christine Vinciguerra, (unknown)	5
7	Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis 2023 ·Hämostaseologie ·Johnny Mahlangu, (unknown), Susan Shapiro, (unknown), Margareth C. Ozelo, Gili Kenet, Flora Peyvandi, (unknown), (unknown), Amy L. Dunn, Jody M. Mason, Doris Quon, Andrew D. Leavitt, Johannes Oldenburg, Hérvè Chambost, Mark T. Reding, (unknown), (unknown), Tara M. Robinson, S. W. PIPE	1
8	Modèle hub & spoke en France : organisation des soins et parcours des patients pour la thérapie génique de l’hémophilie 2023 ·Hématologie ·Yesim Dargaud, Antoine Rauch, Anne Lienhart, Laurent Frenzel, Virginie Barbay, (unknown), (unknown), (unknown), Roseline d’Oiron, Brigitte Pan‐Petesch, Geneviève Piétu, (unknown), Catherine Ternisien, B. Wibaut, Hérvè Chambost	3
9	Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B 2023 ·Blood Advances ·Amy D. Shapiro, Roshni Kulkarni, Margaret V. Ragni, Hérvè Chambost, Johnny Mahlangu, (unknown), Beatrice Nolan, Margareth C. Ozelo, Meredith C. Foster, Annemieke Willemze, (unknown), Nisha Jain, Bent Winding, Jennifer Dumont, Stefan Lethagen, Chris Barnes, John Pasi	4
10	Long‐term immunogenicity, efficacy and tolerability of simoctocog alfa in patients with severe haemophilia A who had completed the NuProtect study in previously untreated patients 2023 ·Haemophilia ·Mary Mathias, (unknown), Aby Abraham, Mark Belletrutti, Manuel Carção, Hérvè Chambost, Anthony K.C. Chan, (unknown), Jonathan M. Ducore, Thierry Lambert, (unknown), (unknown), (unknown), John K. Wu, Anna Klukowska	1
11	Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand 2023 ·Research and Practice in Thrombosis and Haemostasis ·María Román, Amy D. Shapiro, Margaret V. Ragni, (unknown), (unknown), Johan Szamosi, (unknown), Hérvè Chambost	2
12	Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra^®): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP) 2019 ·Haemophilia ·Sophie Susen, Yves Gruel, Anne Godiér, Annie Harroche, Hérvè Chambost, Dominique Lasne, Antoine Rauch, Stéphanie Roullet, Pierre Fontana, Jenny Goudemand, Emmanuel de Maistre, V. Chamouard, B. Wibaut, Pierre Albaladejo, Claude Négrier	41
13	Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients 2019 ·Haemophilia ·Pierre Chelle, (unknown), Pauline Damien, Michèle Piot, Michel Cournil, Anne Lienhart, (unknown), Hérvè Chambost, Claire Morin, Brigitte Tardy	15
14	Dispositif pluridisciplinaire d’accompagnement des enfants et de leur famille depuis l’annonce diagnostique d’une forme sévère d’hémophilie 2016 ·(unknown), (unknown), (unknown), Céline Falaise, (unknown), (unknown), (unknown), (unknown), Vincent Bréjard, Hérvè Chambost	1
15	Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children 2016 ·Thrombosis and Haemostasis ·Hérvè Chambost, Christoph Male, Thierry Lambert, Susan Halimeh, Tatiana A. Chernova, Maria Elisa Mancuso, Julie Curtin, C. Voigt, Yanyan Li, Iris Jacobs, Elena Santagostino, Gili Kenet, (unknown)	46
16	α1‐antitrypsin Pittsburgh and plasmin‐mediated proteolysis 2016 ·Journal of Thrombosis and Haemostasis ·(unknown), Pierre Suchon, Hérvè Chambost, Pierre‐Emmanuel Morange, Corinne Frère, Marie‐Christine Alessi	2
17	Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A 2014 ·Blood ·Thierry Calvez, Hérvè Chambost, Ségolène Claeyssens‐Donadel, Roseline d’Oiron, V. Goulet, Benoît Guillet, (unknown), (unknown), Chantal Rothschild, V. Roussel‐Robert, Christine Vinciguerra, Jenny Goudemand	108
18	Long-lasting recombinant factor FIX Fc fusion (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study 2013 ·Journal of Thrombosis and Haemostasis ·Jerry S. Powell, Shashikant Apte, Hérvè Chambost, (unknown), Shaun P. Jackson, Neil C. Josephson, Johnny Mahlangu, (unknown), Kathelijne Peerlinck, Geoffrey Allen	4
19	Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data 2007 ·Haemophilia ·Michael Richards, Carmen Altisent, Angelika Bátorová, Hérvè Chambost, G. Dolan, Philippe de Moerloose, Máximo Fraga, Cédric Hermans, Anastasia Karafoulidou, Robert Klamroth, Riitta Lassila, C. Rothschild, (unknown)	54
20	Immune reconstitution and outcome after unrelated cord blood transplantation: a single paediatric institution experience 2000 ·Bone Marrow Transplantation ·P Giraud, Isabelle Thuret, D Reviron, Hérvè Chambost, (unknown), G Novakovitch, Catherine Farnarier, Gérard Michel	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact